CDC to investigate lung diseases associated with vaping

The CDC is helping a handful of Midwest states investigate a “cluster” of lung diseases related to e-cigarette use, the agency announced Aug. 17.

The investigation follows reports of vaping-related injuries. In recent days, the number of injured people has risen to 120 across 15 states.

The injuries are primarily among young adults and adolescents and are caused by vaping, according to the CVC, which noted 94 cases of severe lung illnesses as of August 15.

The link to e-cigarette use is somewhat vague, though the CDC needs more information “to determine what is causing the illnesses, the agency said.

“There is no conclusive evidence that an infectious disease is causing the illnesses,” the CDC’s announcement read.

E-cigarettes have taken off in popularity over the last several years, particularly among young adults and teenagers. While some studies have found their use can help smokers quit, their health impacts are not totally known and still have harmful effects. Plus, some e-cigarette makers have come under fire for selling flavored products that are geared toward younger consumers.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.